Compare PCOR & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCOR | KRYS |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 7.8B |
| IPO Year | 2020 | 2017 |
| Metric | PCOR | KRYS |
|---|---|---|
| Price | $52.66 | $286.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 11 |
| Target Price | $74.19 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 2.4M | 226.4K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.94 | ★ 128.00 |
| EPS | N/A | ★ 1.83 |
| Revenue | ★ $1,322,509,000.00 | $389,130,000.00 |
| Revenue This Year | $15.24 | $38.74 |
| Revenue Next Year | $12.99 | $32.53 |
| P/E Ratio | ★ N/A | $155.12 |
| Revenue Growth | 14.83 | ★ 33.94 |
| 52 Week Low | $46.08 | $123.03 |
| 52 Week High | $82.32 | $303.00 |
| Indicator | PCOR | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | 63.63 |
| Support Level | $46.97 | $254.53 |
| Resistance Level | $58.70 | $293.60 |
| Average True Range (ATR) | 2.38 | 12.17 |
| MACD | 0.11 | 1.47 |
| Stochastic Oscillator | 8.17 | 66.94 |
Procore Technologies Inc is a cloud-based construction management software company. It generates revenue through subscriptions for access to its software products. The company's products include Design Coordination, BIM, Field Productivity, Project Financials, Invoice Management, Portfolio Financials, Capital Planning, Accounting Integrations, and Analytics. The software products are hosted on its cloud-based SaaS construction management platform. Subscriptions are sold for a fixed fee and revenue is recognized ratably over the term of the subscription.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.